Excimer Laser, Serum Markers & Psoriasis

Withdrawn before enrolling · Not applicable

Conditions studied: Psoriasis

In brief

The overall aims for this study are to determine whether UVB excimer laser treatment of psoriasis affects serum inflammatory markers, and to assess hyperpigmentation and erythema with excimer laser treatment. The investigators hypothesize that treatment of psoriasis with UVB delivered via 308 nm excimer laser will decrease the levels of serum inflammatory markers. The investigators hypothesize that treatment will decrease plaque erythema and will result in minimal hyperpigmentation.

Key facts

Study ID

NCT02165657

Run by

University Hospitals Cleveland Medical Center

People needed

0

Starts

2013-09-01

Expected to finish

2017-03-01

Last updated by the study team

2021-07-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years and older
• Male or female with diagnosis of psoriasis
• Psoriasis involvement of 5-15% BSA
• Has been off systemic psoriasis therapies (e.g. retinoids, methotrexate, biologic agents, etc) for at least 4 weeks
• Has been off topical therapies (e.g. calcipotriene, topical steroids) for at least 2 weeks
• Fitzpatrick Skin Types I-VI

You may not qualify if…

• Active history of photosensitivity (e.g. xeroderma pigmentosum, lupus erythematosus, porphyria, severe polymorphous light eruption, solar urticaria)
• Any suspicion that the psoriasis is of the photosensitive variant.
• Any medical condition that could be aggravated or may cause extreme discomfort during the study period.

Where it is running

• University Hospitals Cleveland Medical Center (Concord Site) — Concord, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.